Screener
Edgewise Therapeutics, Inc. EWTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Assets | As of / March 31, 2026 / (unaudited) | As of / December 31, 2025 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $33,211 | $61,148 |
| Marketable securities, available for sale | 466,351 | 468,961 |
| Prepaid expenses and other assets | 10,230 | 13,276 |
| Total current assets | 509,792 | 543,385 |
| Property and equipment, net | 7,396 | 7,831 |
| Operating lease right-of-use asset | 1,334 | 1,387 |
| Total assets | $518,522 | $552,603 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s cash & equivalents?
- Edgewise Therapeutics, Inc. (EWTX) reported cash & equivalents of $33.21M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Edgewise Therapeutics, Inc.'s cash & equivalents decreased by 33.5% year-over-year, from $49.92M to $33.21M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s cash & equivalents has grown at a -10.2% compound annual growth rate (CAGR), from $104.92M to $61.15M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Edgewise Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude